Cytomegalovirus infection in solid organ transplantation.
暂无分享,去创建一个
[1] D. Navarro,et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. , 2011, Enfermedades infecciosas y microbiologia clinica.
[2] F. Baldanti,et al. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection. , 2011, The new microbiologica.
[3] C. Solano,et al. Comparative Evaluation of Three Automated Systems for DNA Extraction in Conjunction with Three Commercially Available Real-Time PCR Assays for Quantitation of Plasma Cytomegalovirus DNAemia in Allogeneic Stem Cell Transplant Recipients , 2011, Journal of Clinical Microbiology.
[4] M. Boeckh,et al. Risk factors for late‐onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis , 2011, Transplant infectious disease : an official journal of the Transplantation Society.
[5] H. Einsele,et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. , 2011, The Lancet. Infectious diseases.
[6] S. Chou,et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients , 2010, Transplant infectious disease : an official journal of the Transplantation Society.
[7] R. Razonable,et al. New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation , 2010, Drugs.
[8] R. Stratta,et al. Defining the Risks for Cytomegalovirus Infection and Disease After Solid Organ Transplantation , 2010, Pharmacotherapy.
[9] M. Schleiss. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. , 2009, Current opinion in molecular therapeutics.
[10] J. Morales,et al. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas–kidney transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[11] Eun Jung Lee,et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] A. Åsberg,et al. Long‐Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] A. Pastor,et al. A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV‐Seropositive Lung Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] Lawrence Corey,et al. Vaccine prevention of maternal cytomegalovirus infection. , 2009, The New England journal of medicine.
[15] Rajiv Khanna,et al. Immunobiology of Human Cytomegalovirus: from Bench to Bedside , 2009, Clinical Microbiology Reviews.
[16] G. Bou,et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] C. Solano,et al. Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant Recipients , 2008, Journal of Clinical Microbiology.
[18] A. Neumann,et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] Y. Baez,et al. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. , 2008, Transplantation proceedings.
[20] H Rollag,et al. Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] A. Limaye,et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] T. Pumarola,et al. The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections , 2007, Transplantation.
[23] V. Emery,et al. Cytomegalovirus in transplantation – challenging the status quo , 2007, Clinical transplantation.
[24] O. Manuel,et al. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. , 2007, Transplantation.
[25] T. F. Smith,et al. Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing , 2006, Clinical Microbiology Reviews.
[26] J. Stoner,et al. Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients , 2005, Annals of Internal Medicine.
[27] G. Boivin,et al. Human Cytomegalovirus Resistance to Antiviral Drugs , 2005, Antimicrobial Agents and Chemotherapy.
[28] G. Snell,et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. , 2004, The Journal of infectious diseases.
[29] B. Alexander,et al. Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] R. Busuttil,et al. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients , 2003, Transplantation.
[31] Hans-Georg Rammensee,et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.
[32] E. Mylonakis,et al. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] P. Griffiths,et al. Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] J. Preiksaitis,et al. The risk of transfusion‐acquired CMV infection in seronegative solid‐organ transplant recipients receiving non‐WBC‐reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center , 2002, Transfusion.
[35] F. Prósper,et al. Qualitative Plasma PCR Assay (AMPLICOR CMV Test) versus pp65 Antigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation , 2001, Journal of Clinical Microbiology.
[36] S. Hunt,et al. IMPACT OF CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN ON OUTCOME AFTER CARDIOTHORACIC TRANSPLANTATION: A Comparative Study of Combined Prophylaxis with CMV Hyperimmune Globulin Plus Ganciclovir Versus Ganciclovir Alone , 2001, Transplantation.
[37] D. Snydman,et al. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] M. Giral,et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. , 2001, Journal of the American Society of Nephrology : JASN.
[39] D. Mclone. The Risk , 2001, Pediatric Neurosurgery.
[40] H. Rollag,et al. A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1 , 2000, Transplantation.
[41] P. Griffiths,et al. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[42] C. Sabin,et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.
[43] J. Squifflet,et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.
[44] J. Aguado,et al. [Prospective study of cytomegalovirus infection in liver transplant recipients]. , 1992, Medicina clinica.
[45] D. Grant,et al. Intestinal transplantation: current status. , 1989, Transplantation proceedings.
[46] R. Bevan,et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. , 1988, Reviews of infectious diseases.
[47] W. V. van Son,et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes , 1988, Journal of medical virology.
[48] H. Friedman,et al. TOWNE-VACCINE-INDUCED PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTS , 1984, The Lancet.
[49] Angela M Caliendo,et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. , 2010, Transplantation.
[50] I. Sia,et al. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. , 2000, Clinical microbiology reviews.
[51] J. Wetzels,et al. Nephrology Dialysis Transplantation the Influence of Mycophenolate Mofetil on the Incidence and Severity of Primary Cytomegalovirus Infections and Disease after Renal Transplantation , 2022 .